Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 2,500 hematologic oncology specialists to participate in the upcoming Tenth Annual Meeting of the Society (SOHO 2022). Click for more information and registration.

Register now
  • 6,266 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of nearly 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

Lenalidomide, Bortezomib, and Dexamethasone Plus AHSCT Leads to Significant PFS Improvement in Myelo

This triplet drug regimen plus AHSCT led to a highly significant PFS benefit, especially for those with high-risk cytogenetics, in patients with newly diagnosed MM.

Pegasparaginase-Based Treatment Regimen Shows Promising Results in Extranodal NKTCL

A pegasparaginase-based treatment regimen improved survival rates and had lower toxicity than an asparagine-based regimen in patients with newly diagnosed advanced-stage extranodal NKTCL.

Cusatuzumab Has Antitumor Activity in R/R CTCL

A CD70-directed monoclonal antibody had antitumor activity in highly pre-treated patients with CD70-positive R/R CTCL, including those with Sézary syndrome.

Oncolytic Virotherapy Leads to Durable Disease Remissions in R/R T-Cell Lymphoma

Investigators are expanding a clinical trial of an oncolytic virotherapy treatment for hematologic malignancies after the treatment led to responses in patients with R/R T-cell lymphoma.

HMA Therapy Associated with Favorable Long-Term Clinical Outcomes in Lower-Risk MDS

Results from a phase II study showed that the response to HMA therapy was associated with favorable clinical outcomes in lower-risk MDS.

FDA Grants Orphan Drug Designation to Investigational Small-Molecule Inhibitor DSP-5336 for AML

DSP-5336 is currently being investigated in a phase I/II clinical trial to evaluate its safety and efficacy in patients with relapsed or refractory AML/ALL.

European Commission Approves Ibrutinib in Fixed-Duration Combination Regimen for Adult Patients with

The approval is based on the phase III GLOW study that demonstrated superior progression-free survival in patients treated with ibrutinib plus venetoclax.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top